http://rdf.ncbi.nlm.nih.gov/pubchem/reference/232710

Outgoing Links

Predicate Object
contentType Journal Article|Review
endingPage 898
issn 1744-7658
1354-3784
issueIdentifier 4
pageRange 885-898
publicationName Expert Opinion on Investigational Drugs
startingPage 885
bibliographicCitation Massi-Benedetti M, Damsbo P. Pharmacology and clinical experience with repaglinide. Expert Opin Investig Drugs. 2000 Apr;9(4):885–98. doi: 10.1517/13543784.9.4.885. PMID: 11060717.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e2d9ba66917704f2692c8ef7720105e8
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f8111e46cd8b77c1778a8b12e654c54a
date 200004
identifier https://pubmed.ncbi.nlm.nih.gov/11060717
https://doi.org/10.1517/13543784.9.4.885
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/21889
https://portal.issn.org/resource/ISSN/1354-3784
https://portal.issn.org/resource/ISSN/1744-7658
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Pharmacology and clinical experience with repaglinide
discusses http://id.nlm.nih.gov/mesh/M0016885
http://id.nlm.nih.gov/mesh/M0010903
http://id.nlm.nih.gov/mesh/M0003327
http://id.nlm.nih.gov/mesh/M0196126
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fa5fc799a3f3c6277beeb3473c262800
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID65981
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_f1ef7af3407e96ea02497b2009be8786
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_55029e08d2afcf59a719caf55a149021
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_cdf1e220d89c2dcd2e000c3d105bf93e
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4091
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10923
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5591
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7444
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5793
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8121

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID46508150

Total number of triples: 37.